CARTITUDE-2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
80
Last Updated
6 days ago
Am I Eligible

Participating Centers

There are 29 centers participating in this trial. Enter a location below to find the closest center.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.